The state Supreme Court has decided against taking up two hormone-replacement therapy cases involving the drug Prempro and whether it caused breast cancer, letting stand an $11.2 million verdict against Wyeth Pharmaceuticals in one and a defense verdict in favor of the drugmaker in another.
The justices denied allocatur in Barton v. Wyeth Pharmaceuticals and Henry v. Wyeth Pharmaceuticals on October 16.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
